2016 9 month interim update Brussels, 25 October 2016 Mariana, living with epilepsy
Disclaimer and safe harbor Forward-looking statements 2016 9M interim update - 2 This presentation contains forward-looking statements, including, without limitation, statements containing the words believes, anticipates, expects, intends, plans, seeks, estimates, may, will, and continue and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation. Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
2016 9M interim update - UCB is progressing on its strategic growth path in 2016 3 Patient Value Strategy delivers shareholder value Strong growth Growth expansion Breakthrough phase Grow Cimzia, Vimpat and Neupro Combined net sales: 1.736 billion (+18%) Advance and prepare growth expansion Briviact (brivaracetam) launched Romosozumab: filed in the U.S. Deliver breakthrough solutions Strong early pipeline with 10 NMEs 1 Continued focus Nitrates divested 2016 financial outlook confirmed Mid-term target: Competitive 30% rebitda margin in 2018 1 NME: New Molecular Entity
9 months key product performance On track to deliver FY 2016 guidance 2016 9M interim update - 4 9M 2016 9M 2015 Variance million Actual Actual CER Revenue 3 075 2 864 7% 7% Immunology / Cimzia 933 775 20% 21% Neurology* 1 361 1 260 8% 9% Vimpat 583 495 18% 19% Keppra 541 565-4% -3% Briviact 11 Neupro 219 199 10% 11% Numbers may not add due to rounding CER: constant exchange rate * include multiple sclerosis therapies in Asia (partner: Biogen)
Romosozumab in bone loss disorders 2016 9M interim update - 5 Potential important treatment option for osteoporosis STRUCTURE: Phase 3 active-controlled study in postmenopausal women with osteoporosis (Sep 2015) FRAME: Phase 3 placebo-controlled study in postmenopausal women with osteoporosis (Feb 2016) BRIDGE: Phase 3 placebo-controlled study in men with osteoporosis (Mar 2016) Manorama, living with osteoporosis Biologic License Application (BLA) filed with U.S. FDA* (Sep 2016) ARCH: Phase 3 active-controlled study in postmenopausal women with osteoporosis (expected H1 2017) FRAME co-primary endpoints: reducing the incidence of new vertebral fractures through 12 and 24 months BRIDGE primary endpoint: increasing bone mineral density (BMD) at the lumbar spine at 12 months FDA: Food and Drug Administration
2016 9M interim update - Early pipeline to deliver breakthrough solutions 6 10 NMEs* in early clinical development dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus bimekizumab (IL17A/F) various indications Learn phase POC 1 Phase 1 Phase 2 Confirm phase Phase 3 Phase 2b results H2 2018 (Partner: Biogen) Phase 2b start: Sept. 2016 Filing bimekizumab add-on to Cimzia rheumatoid arthritis UCB0942 (PPSI) highly drug resistant epilepsy seletalisib (PI3K δ inhibitor) Sjögren s syndrome + APDS (Phase 1b) UCB7665 immune thrombocytopenia UCB1332 - Parkinson s disease UCB4144 / VR942 - asthma UCB6673 - immunological diseases (Partner: Neuropore) Phase 2a results: H1 2017 Phase 2a results: Q1 2017 Phase 2a results: 2017 Phase 2a results: Q3 2017 Phase 2a start: 2017 (Partner: Vectura) (Partner: King s College London) UCB3491 - epilepsy UCB7858 - auto-inflammatory diseases neurology immunology New Molecular Entity 1 Proof of concept
2016 financial outlook confirmed Trending towards the upper end of the ranges 2016 9M interim update - 7 2016 guidance Revenue rebitda Core EPS ~ 4.0-4.1 billion ~ 970-1 010 million ~ 2.90-3.20 Continued growth: Cimzia, Vimpat, Neupro Expected R&D expense ratio of ~28% (+/-1% point) Expected underlying tax ratio in the "high twenties" ~188 million shares weighted average outstanding Mid-term guidance Recurring EBITDA of 30% in 2018 Net debt / rebitda ratio of 1:1 by 2018 Cimzia, Vimpat, Neupro combined peak sales of at least 3.1 billion by 2020
UCB's strategic growth path 2016 9M interim update - 8 True differentiation drives leadership and sustainability Strong growth Cimzia, Vimpat, Neupro + Keppra Growth expansion by Briviact + romosozumab Breakthrough phase - Growth expansion by next wave products
Strong Cimzia performance across all regions 2016 9M interim update - 9 Cimzia Net sales million 9M 2016 9M 2015 Actual CER 1 Crohn s disease rheumatoid arthritis psoriatic arthritis axial spondyloarthritis / ankylosing spondylitis 1 083 million 2015 net sales 1.5 billion expected peak sales by 2020 2024 patent expiry (U.S. & EU) Astellas (Japan - 2012) Dermira (psoriasis - 2014) Phase 3 Psoriasis nr axial spondyloarthritis² (U.S.) Filed juvenile idiopathic arthritis (U.S.) U.S. 588 512 15% 15% Europe 258 212 22% 24% Japan 25 5 > 100% > 100% International markets 62 46 35% 42% Total Cimzia 933 775 20% 21% C-EARLY Phase 4 results EXXELERATE Phase 4 results juvenile IA³ Phase 3 results R&D milestones 2016 > 2017 juvenile IA³ filing (U.S.) RA - Phase 3 results (China) Auto-injector CHMP positive opinion (EU) psoriasis Phase 3 results (first data) women in child bearing age Phase 4 results psoriasis Phase 3 results (3 studies) Numbers may not add due to rounding 3 IA: idiopathic arthritis 1 CER: constant exchange rates 4 RA: rheumatoid arthritis 2 nr axspa: non-radiographic axial spondyloarthritis
Strong neurology portfolio performance Leading epilepsy company: The right product for the right patient at the right time 2016 9M interim update - 10 Net sales million 9M 2016 9M 2015 Actual CER Briviact 11 Vimpat 583 495 18% 19% Keppra 541 565-4% -3% Total epilepsy 1 136 1 060 7% 8% Neupro 219 199 10% 11% Neurology other 6 2 > 100% > 100% Total Neurology 1 361 1 260 8% 9% Numbers may not add due to rounding 1 CER: constant exchange rates
Vimpat performance 2016 9M interim update - 11 Robust growth in all markets, launch in Japan Vimpat Epilepsy POS 1 679 million 2015 net sales 1.2 billion expected peak sales by 2020 2022 patent expiry (U.S. & EU) Daiichi Sankyo (Japan - 2014) Phase 3 Epilepsy POS 1 pediatric Epilepsy PGTCS² Filed Epilepsy POS 1 mono (EU) Net sales million 9M 2016 9M 2015 Actual CER 1 U.S. 440 373 18% 18% Europe 114 98 16% 16% Japan 3 International markets 26 23 13% 19% Total Vimpat 583 495 18% 19% epilepsy POS 1 - monotherapy filing (EU) epilepsy POS 1 adj. therapy approval (Japan) 2016 R&D milestones epilepsy POS 1 ped. - adj. therapy filing (EU) U.S. District Court confirms validity of patent epilepsy POS 1 - monotherapy filing (Japan) > 2017 epilepsy POS 1 ped. adj. therapy Phase 3 results Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures 2 Primary Generalized Tonic-Clonic Seizures
Keppra performance 2016 9M interim update - 12 Continued in-market demand Keppra epilepsy POS 1 epilepsy PGTCS² epilepsy myoclonic seizures 737 million 2015 net sales 1.2 billion peak sales (2008) Status of exclusivity: Japan - until 2018 U.S.³ - Nov. 2008 Europe - Sep. 2010 Net sales million 9M 2016 9M 2015 Actual CER U.S. 151 189-20% -20% Europe 184 186-1% 1% Japan 77 68 13% 2% International markets 129 122 6% 13% Total Keppra 541 565-4% -3% R&D milestones Otsuka (Japan - 2008) epilepsy PGTCS 2 adj. therapy - approval (Japan) Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures 2 Primary Generalized Tonic-Clonic Seizures 3 Keppra XR expired in Sep. 2011
Briviact launch 2016 9M interim update - 13 New treatment option for patients living with epilepsy Briviact Epilepsy POS 1 add on therapy Available to patients in: Canada Denmark Germany Netherlands Norway U.K. U.S. 2026 patent expiry (U.S. & EU) Net sales million 9M 2016 9M 2015 Actual CER U.S. 5 Europe 6 International markets 0 Total Briviact 11 R&D milestones epilepsy POS 1 adj. therapy approval (EU) epilepsy POS 1 adj. therapy approval (U.S.) epilepsy POS 1 adj. therapy launch (U.S.) epilepsy POS 1 adj. therapy launch (EU) epilepsy POS 1 adj. th. approval (Canada) Numbers may not add due to rounding CER: constant exchange rate 1 Partial-onset seizures
Neupro performance 2016 9M interim update - 14 Growing in all geographies Neupro Net sales million 9M 2016 9M 2015 Actual CER Parkinson s disease restless legs syndrome 258 million 2015 net sales 400 million expected peak sales by 2020 2021 patent expiry (U.S. & EU) U.S. 57 56 3% 3% Europe 122 110 11% 12% Japan 30 26 17% 17% International markets 10 8 27% 34% Total Neupro 219 199 10% 11% Otsuka (Japan - 2002) Numbers may not add due to rounding CER: constant exchange rate
Osteoporosis: a silent disease 2016 9M interim update - 15 Globally, osteoporosis causes ~8.9m fractures per year 1 Men are most likely to break bones from osteoporosis later in life, making it more difficult to recover. 2 Postmenopausal osteoporosis (PMO) is the most common form of the disease. 3 PMO is a silent disease that cannot be seen or felt, and often goes undetected until a fracture occurs. 4 a fracture every 3 seconds 1 vertebral fracture is the most common osteoporotic fracture 5 1. International Osteoporosis Foundation. Osteoporosis Facts and Statistics. 2. National Osteoporosis Foundation. The Man s Guide to Osteoporosis. 2011. 3. American Academy of Orthopaedic Surgeons. Position Statement: Osteoporosis/Bone Health in Adults as a National Public Health Priority. 4. International Osteoporosis Foundation. What Is Osteoporosis? 2015. 5. Vertebral Fracture Initiative - Overview of osteoporosis: Epidemiology and clinical management
Romosozumab development 2016 9M interim update - 16 Phase 3 program in bone loss disorders Registrational studies in osteoporosis STRUCTURE FRAME BRIDGE ARCH (NCT01796301) (NCT01575834) (NCT02186171) (NCT01631214) 436 patients (postmenopausal women) 7 180 patients (postmenopausal women) 245 patients (men) 4 094 patients (postmenopausal women) Duration 12 months romosozumab 12 months romosozumab + 12 months denosumab 12 months romosozumab 12 months romosozumab + 12 months alendronate omparator teriparatide 12 months placebo + 12 months denosumab 12 months placebo 24 months alendronate Endpoint BMD DXA % change at the hip Incidence of new vertebral fracture BMD DXA % change at the lumbar spine Incidence of clinical fracture + incidence of new vertebral fractures at month 24 "Results" ENDO 2016 ASBMR 2016 ACR 2016 H1 2017 osteoporosis in postmenopausal women filing (U.S.)
Romosozumab development 2016 9M interim update - 17 FRAME Phase 3 results 7 180 patients Average BMD T-score : -2.5 (hip) / -2.7 (lumbar) romosozumab 12 months placebo 12 months denosumab 12 months denosumab 12 months Co-Primary endpoints: incidence of new vertebral fractures 12 months 12 months 24 24 months months Secondary endpoint: incidence of clinical fracture @ 12months 12 months 24 24 months months
Bimekizumab/UCB4940 (anti-il-17a and anti-il-17f) 2016 9M interim update - 18 What is Bimekizumab? Structure Target IL-17F IL-17F homodimer IL-17A IL-17A homodimer IL-17A IL-17F heterodimer Bimekizumab is an immunoglobulin G1-κ humanised monoclonal antibody Bimekizumab is a dual IL-17A and IL- 17F inhibitor Bimekizumab Drug Profile: http://adisinsight.springer.com/drugs/800037676. Accessed 30/11/2015.
Further facts and figures
Strengthening UCB's Patient Value Strategy 2016 9M interim update - 20 Patient Value Strategy Shift from volume to patient value creation Innovation Strategy Differentiation Networked Strategy Competitive strengths + external connections Growth Strategy Top and bottom line growth delivering value Shareholder value
Growth drivers Core medicines tracking well towards peak sales target of 3.1 billion by 2020 2016 9M interim update - 21 EXPECTED AT LEAST 1.5 billion peak sales EXPECTED AT LEAST 1.2 billion peak sales EXPECTED AT LEAST 400 million peak sales Inflammatory arthritis indications and Crohn s disease Epilepsy partial-onset seizures Parkinson s disease and Restless Legs Syndrome Psoriasis: strategic collaboration with Dermira Monotherapy in the U.S. Partner in Japan: Daiichi Sankyo Partner in Japan: Otsuka
Cimzia in-market performance (Aug 2016) 2016 9M interim update - 22 Strong growth in rheumatology indications U.S. Europe Japan 10% 8% 6% 4% 2% Cimzia vs. Rheumatology 1 Market Growth 2.1% 3.4% 6.9% +4.7% 30% 25% 20% 15% 10% 5% Cimzia vs. Rheumatology 1 Market Growth 22.6% 22.7% 24.8% +2.2% 30% 25% 20% 15% 10% 5% Cimzia vs. RA Market Growth 10.1% 13.5% 21.1% +11.0% 0% Anti TNF Biologics Cimzia 0% Anti TNF Biologics Cimzia 0% Anti TNF Biologics Cimzia 6.0% 5.5% 5.0% 4.5% Cimzia Rheumatology 1 R3M Patient Share +0.1% 4.5% 8.5% 8.0% 7.5% 7.0% Cimzia Rheumatology 1 R3M Patient Share 8.1% +0.8% 4.5% 4.0% 3.5% 3.0% Cimzia RA R3M Patient Share 3.8% +0.4% 4.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source: U.S. IMS Source of Business Report 6.5% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source: IMS MIDAS In-Market KPI s are based on Exit Patients 2.5% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source: IMS MIDAS; Cimzia patients are considered 100% in RA In-Market KPI s are based on Exit Patients 1 Rheumatology includes RA, AS/AxSPA and PSA indications Shares calculated based on Anti-TNF market. In-market growth is calculated for MAT Aug'15 vs. Aug'16 Market share is calculated for Aug 16 and market share growth is shown against R3M Aug 15
Vimpat in-market performance (Aug 2016) 2016 9M interim update - 23 A leading therapeutic option in the AED market U.S. Europe Japan 20% 15% Vimpat vs. AED Market Growth (TRx) 16.0% 20% 15% Vimpat vs. AED Market Growth (TDx) 18.3% 10% 5% 0% 4.7% AED Market Vimpat +11.3% 10% 5% 0% -5% -0.3% AED Market Vimpat +18.6% Vimpat approved (July 2016) and launched (Aug 2016) 4.0% 3.8% Vimpat R3M TRx Share 3.8% 3.0% 2.8% Vimpat R3M TDx Share 2.9% 3.6% 2.6% +0.4% 3.4% 3.2% +0.3% 2.4% 2.2% 3.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data U.S.: U.S. IMS NPA In-Market KPIs are based on TRx 2.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data EU: IMS MIDAS In-Market KPI s are based on TDx AED = anti epileptic drug - AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. AED Market and Vimpat growth are calculated for MAT Aug'16 vs. MAT Aug'15. Vimpat market share is calculated for R3M Aug'16 and market share growth is shown against R3M Aug'15
Keppra in-market performance (Aug 2016) 2016 9M interim update - 24 U.S. Europe Japan 6.0% 4.0% 2.0% 0.0% -2.0% -4.0% -6.0% -8.0% -10.0% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% Keppra vs. AED Market Growth (TRx) 4.7% AED Market Keppra R3M TRx Share -9.0% 0.9% 0.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data U.S.: U.S. IMS NPA In-market KPI s are based on TRx Keppra -13.6% -0.2% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% -2.0% -4.0% 14.0% 13.5% 13.0% 12.5% 12.0% 11.5% 11.0% 10.5% Keppra vs. AED Market Growth (TDx) -0.3% AED Market Keppra R3M TDx Share 6.9% Keppra 12.4% 10.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx +7.2% +0.9% 50% 40% 30% 20% 10% 0% 12.5% 12.0% 11.5% 11.0% 10.5% 10.0% 9.5% 9.0% Keppra vs. AED Market Growth (TDx) 2.1% AED Market Keppra R3M TDx Share 40.0% Keppra +37.9% 12.5% +3.5% 8.5% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. For U.S, Keppra includes Keppra XR. For EU, Keppra does not include UCB Levetiracetam. AED Market and Keppra TRx growth are calculated for MAT Aug'16 vs. MAT Aug'15. Keppra TRx market share is calculated for R3M Aug'16 and market share growth is shown against R3M Aug'15
2016 9M interim update - 25 Expanding our portfolio, creating sustainable patient value Helping individuals live at their ideal is the core of our strategy Meeting the need for immediate control and clarity of response Establishing a new foundational therapy for focal epilepsies with an ideal profile Heritage to accelerate the value shift from old to new 1 Hope and Trust UCB Sponsored ethnographic research, among the largest and most robust ever conducted in epilepsy
Introducing Briviact in epilepsy POS 1 New epilepsy treatment for patients experiencing uncontrolled partial-onset seizures 2016 9M interim update - 26 Our newest solution Now approved in EU (Jan 2016) and U.S. (Feb 2016) 2 One of the largest Phase 3 programs in epilepsy involving over 1 550 patients Guoqiong, living with epilepsy Statistically significant AND clinically relevant results³ BRIVIACT Meeting the need for immediate control and clarity of response Guided by patient insights: Life in Between Patients spend their life waiting for: Seizure control The need to know 1 POS: partial-onset seizures 2 Briviact received Drug Enforcement Administration (DEA) scheduling in May 2016 3 The most commonly reported adverse events were somnolence, dizziness, fatigue and headache. Source: UCB data on file
Neupro in-market performance (Aug 2016) 2016 9M interim update - 27 Growth in a genericized market U.S. Europe Japan 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% -2.0% 8.5% 8.0% 7.5% 7.0% 6.5% Neupro PD vs. PD (KC) Market Growth (TRx) 0.1% 0.1% PD Market PD Key Neupro Competitors Neupro PD R3M TRx Share 6.7% 6.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data U.S.: U.S. IMS NPA In-market KPI s are based on TRx 2.1% +2.1% -0.3% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% 18.5% 18.0% 17.5% 17.0% 16.5% Neupro PD vs. PD (KC) Market Growth (TDx) 2.6% 2.4% PD Market PD Key Competitors Neupro PD R3M TDx Share 10.1% Neupro 17.8% 16.0% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx +7.8% +1.3% 35% 30% 25% 20% 15% 10% 5% 0% 28% 26% 24% 22% Neupro PD vs. PD (KC) Market Growth (TDx) 0.5% PD Market 1.9% PD Key Competitors Neupro PD R3M TDx Share 30.1% Neupro +28.2% 25.8% +4.9% 20% Aug-15 Nov-15 Feb-16 May-16 Aug-16 Source data EU, JP: IMS MIDAS In-market KPI s are based on TDx PD market: All molecules in ATC3= N4A. In the EU and Japan, the TDx of all these molecules are factored for PD usage. In the US, only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usage. PD Key Competitors (KC) market: The 8 DA s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole. In the US, only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.
UCB HY 2016 financial highlights 2016 9M interim update - 28 Continued delivery on growth strategy top and bottom line Revenue Net sales up by 10% (9% CER) to 1 876 million Continued net sales growth of core products Total operating expenses Overall operating expense ratio improved partly due to R&D expense phasing Recurring EBITDA Higher gross profit and decrease of operating expenses Net profit of the Group 300 million attributable to UCB shareholders (+12%) Core earnings per share Based on 188 million weighted average shares outstanding (2015: 192 million) 2 019 million 1 015 million 549 million 316 million 1.72 Actual +5% -2% CER +5% 0% +18% +11% +9% 0% +46% +34%
Top and bottom line growth improved ratios* 2016 9M interim update - 29 Sustainable growth and margin improvement Gross margin ratio 69% 70% 72% 30% ~24% FY 2014 FY 2015 HY 2016 Total operating expense ratio 57% 55% 50% FY 2014 FY 2015 HY 2016 21% 18% 17% FY 2013 FY 2014 FY2015 FY2016e 2018e rebitda ratio tracking towards mid-term target * versus revenue
Debt maturity schedule (@ 30 June 2016) KU divestiture enhances financial and strategic flexibility Perpetual bond called in March 2016 2016 9M interim update - 30 ( million) 815 571 58 Liquid assets 368 368 350 243 118 500 176 168 350 350 250 18 18 176 75 13 2016 2017 2018 2019 2020 2021 2022 2023 beyond Belgian Commercial Paper Belgian retail bond Institutional eurobond Other loans EIB loan
One UCB today: A Global Player Presence in 38 countries completed by a robust network of partners 2016 9M interim update - 31 7 643 employees globally 2 RESEARCH CENTERS Braine-l Alleud (Belgium) Slough (U.K.) 3 DEVELOPMENT HUBS Monheim (Germany) RTP North Carolina (U.S.) Tokyo (Japan) 4 MANUFACTURING FACILITIES Braine-l Alleud (Belgium) Zuhai (China) Saitama (Japan) Bulle (Switzerland) June 2016
Shareholder structure 2016 9M interim update - 32 Stable shareholder base with free-float of 61% Total number of shares: 194.5 million Weighted average shares outstanding in 2016: 188 million Free float investors by region Source: Notifications and UCB underlying ownership analysis
Your UCB Investor Relations team 2016 9M interim update - 33 ן Antje Witte, Vice President Investor Relations Phone: +32 2 559 9414 E-mail: antje.witte@ucb.com ן Isabelle Ghellynck, Director Investor Relations Phone: +32 2 559 9588 E-mail: isabelle.ghellynck@ucb.com ן Nathalie Deldime, Investor Relations Manager Phone: +32 2 559 9291 E-mail: nathalie.deldime@ucb.com ן Check out our new IR App stay tuned wherever you go